Literature DB >> 8417011

6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.

H Hoshi1, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde.   

Abstract

In 11 normal volunteers and six patients with Parkinson's disease, we compared six different analyses of dopaminergic function with L-3,4-dihydroxy-6-[18F]fluorophenylalanine (FDOPA) and positron emission tomography (PET). The caudate nucleus, putamen, and several reference regions were identified in PET images, using magnetic resonance imaging (MRI). The six analyses included two direct determinations of DOPA decarboxylase activity (k3D, k3*), the slope-intercept plot based on plasma concentration (K), two slope-intercept plots based on tissue content (k3r, k3s), and the striato-occipital ratio [R(T)]. For all analyses, the difference between two groups of subjects (normal volunteers and patients with Parkinson's disease) was larger in the putamen than in the caudate. For the caudate nucleus, the DOPA decarboxylase activity (k3D, k3*), tissue slope-intercept plots (kr3, ks3); and striato-occipital ratio [R(T)] analyses significantly discriminated between the normal volunteers and the patients with Parkinson's disease (p < 0.005) [with least significance for k3* (p < 0.05)], while the plasma slope-intercept plot (K) failed to do so. For the putamen, the values for k3D, k3*, K, k3r, k3s, and R(T) of normal volunteers were significantly higher than those of patients (p < 0.005) [with least significance for K (p < 0.025)]. Linear correlations were significant between k3D and k3s; k3D and k3r; k3D and R(T); and k3D and k3*, in this order of significance. We found no correlation between k3D and K values in the caudate nucleus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417011     DOI: 10.1038/jcbfm.1993.8

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  21 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 2.  Neuroimaging methods applied in Parkinson's disease.

Authors:  Klaus L Leenders
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

Authors:  I Lopes Alves; Sanne K Meles; Antoon Tm Willemsen; Rudi A Dierckx; Ana M Marques da Silva; Klaus L Leenders; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-19       Impact factor: 6.200

4.  (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Authors:  Aaron F Struck; Lance T Hall; Joanna E Kusmirek; Catherine L Gallagher; John M Floberg; Christine J Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Common Variation in the DOPA Decarboxylase (DDC) Gene and Human Striatal DDC Activity In Vivo.

Authors:  Daniel P Eisenberg; Philip D Kohn; Catherine E Hegarty; Angela M Ianni; Bhaskar Kolachana; Michael D Gregory; Joseph C Masdeu; Karen F Berman
Journal:  Neuropsychopharmacology       Date:  2016-02-29       Impact factor: 7.853

6.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

7.  Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

Authors:  M Itoh; K Meguro; T Fujiwara; J Hatazawa; R Iwata; K Ishiwata; T Takahashi; T Ido; H Sasaki
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

8.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

9.  Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET.

Authors:  Keisuke Matsubara; Yoko Ikoma; Maki Okada; Masanobu Ibaraki; Tetsuya Suhara; Toshibumi Kinoshita; Hiroshi Ito
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

10.  Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases.

Authors:  David S Goldstein; LaToya Sewell
Journal:  Parkinsonism Relat Disord       Date:  2009-02-07       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.